Rare Gastrointestinal Tumors
Rare Gastrointestinal Tumors Van Karlyle Morris Ben George Anal With approximately 9000 cases are expected to occur annually (1), squamous cell carcinoma of the anal canal is considered a rare…
ONCOLOGY
Pancreatic Cancer
Pancreatic Cancer Michael Sangmin Lee Tanios Bekaii-Saab Shubham Pant Introduction Pancreatic cancer is the third most common cancer causing mortality in the United States. Despite improvements in mortality rates observed…
Biliary Tract Cancer
Biliary Tract Cancer Sunyoung S. Lee Milind Javle Molecular Targeted Therapy The molecular analyses of molecular profiling show that up to 35% of patients with cholangiocarcinoma have potentially targetable genomic…
Liver Cancer (Hepatocellular)
Liver Cancer (Hepatocellular) Irene S. Yu Ahmed O. Kaseb Introduction An estimated 42,230 new cases of liver cancer are diagnosed in the United States annually, with the majority comprised of…
Colorectal Cancer
Colorectal Cancer Christine Parseghian Targeting RAS CETUXIMAB Cetuximab is a chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR). It does not benefit patients with…
Radiation Therapy
Radiation Therapy Beth McLellan ACUTE RADIATION DERMATITIS Acute radiation dermatitis (RD) occurs within 90 days after radiation therapy (RT). It is most common among patients with breast, head and neck,…
Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Inhibitors
Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Inhibitors Jesse Hirner Brittany A. Klein Anna Kristine Dewan Programmed cell death 1 (PD-1) is a receptor found on T…
Thalidomide and Lenalidomide
Thalidomide and Lenalidomide Pearl O. H. Ugwu-Dike Yevgeniy Semenov Thalidomide and lenalidomide are antiangiogenic, antineoplastic, immunomodulatory agents used in the management of a wide range of conditions. Thalidomide, historically used…
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Michael S. Chang Rebecca I. Hartman Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) functions as an immune checkpoint in negatively regulating T-cell function. T-cell activation requires…
